FDA approves treatment for refractory multiple myeloma
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
List view / Grid view
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
A Phase III clinical development programme testing otilimab in patients with RA has begun.
The filler market is predicted to increase to US$2 billion by 2024, according to a new report.
The price of over 3400 drugs have been hiked in the first half of 2019, surpassing the number of hikes imposed during the same period last year.
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
A study has shown the warning letters the FDA distributes have decreased by a third since Trump came to office.
Macleods has issued a recall of 32 lots of drug products that contained trace amounts of NMBA impurities.
The MHRA has given marketing authorisation for short-term jet-lag therapy in adults.
The ABPI has reported findings from its transparency initiative, Disclosure UK, stating that R&D investment grew significantly from 2017 to 2018.
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
The EMA has given its approval recommendation to three drugs and announced negative opinions for approval on others.
AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Allergan.
According to Reuters, GSK has started the sale of some consumer health brands as it seeks to raise £1 billion.
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.